Apple (Mal d 3) IgE Test · Blood

If you have reacted unexpectedly to fruits, nuts, or legumes, or you have unexplained reactions that point to something beyond a typical pollen-fruit issue, the answer may lie in a specific protein family called nsLTP (non-specific lipid transfer proteins). Apple (Mal d 3) IgE is one piece of a larger picture: it tells you whether your immune system has built antibodies against the lipid transfer protein in apples, which often signals sensitization to related proteins in many other plant foods.

This is a research-grade component test, not a yes-or-no diagnosis. A positive result rarely means apples are the problem. More often, it flags a broader pattern of plant-food sensitization that warrants attention, especially if you have had reactions to peaches, hazelnuts, walnuts, or peanuts.

What This Antibody Actually Reflects

Mal d 3 (the lipid transfer protein from apple) belongs to a family of plant defense proteins called nsLTPs that are unusually stable. They survive cooking, stomach acid, and digestion intact, which is why nsLTP sensitization can sometimes trigger reactions to processed and cooked plant foods, not just raw ones. When your immune system encounters these proteins and mistakes them for a threat, B cells (a type of white blood cell) produce IgE antibodies (immunoglobulin E) that recognize them. The blood test measures the concentration of those antibodies.

Sensitization to Mal d 3 typically does not arise in isolation. It clusters with antibodies to nsLTPs in peach (Pru p 3), hazelnut, walnut, peanut, and other plant foods, and in some regions, with antibodies to mugwort pollen. This pattern is what makes Mal d 3 IgE more interesting as a marker of a sensitization profile than as a stand-alone diagnostic test for apple allergy.

Why It Is a Poor Test for Apple Allergy Specifically

Most apple allergy in birch-pollen regions is driven by a different apple protein, Mal d 1, not Mal d 3. In a Northern China cohort of 40 apple-sensitized patients, Mal d 1 was the strongest diagnostic component, while Mal d 3 was present in only a minority of patients and most of those did not actually react to apple. The test had limited diagnostic value for apple allergy or for predicting severity in that population.

Geography changes the interpretation. In Mediterranean regions, where nsLTP allergy is more common, Mal d 3 sensitization has been linked to systemic reactions to apple. In Northern Europe and Northern China, the same antibody more often points to mugwort-driven food allergy syndromes or broader nsLTP sensitization without severe apple reactions.

Reconciling the Mixed Picture

It can seem contradictory that the same antibody predicts severe systemic reactions in one part of the world and is a benign incidental finding in another. The resolution is that Mal d 3 IgE is not a one-number verdict on apple allergy. It is a phenotype marker for nsLTP sensitization, and the clinical risk that comes with it depends on the constellation of other sensitizations, the local prevalence of LTP allergy, and your individual symptom history. The same antibody in someone with co-sensitization to peach LTP (Pru p 3) in Spain and someone with co-sensitization to mugwort pollen in Beijing reflects two very different clinical situations.

Connection to Broader Plant-Food Allergy

In Northern China, Mal d 3-sensitized patients were also commonly sensitized to mugwort, and these patients had a higher risk of generalized allergy to peach, nuts, or legumes. In a Lithuanian cohort, roughly a quarter of atopic adults with rhinitis, asthma, or food allergy were sensitized to nsLTPs, with Mal d 3 frequently among them. The authors of that cohort suggested nsLTP component testing as a first-line tool when evaluating anaphylaxis of unknown origin.

If you have had unexplained systemic reactions and no clear trigger has been identified, a positive Mal d 3 IgE is a reason to investigate the broader nsLTP family rather than to focus on avoiding apples alone.

How It Compares to Other Apple Tests

The performance numbers below come from different patient groups and different testing methods. They are useful for orientation, not for direct comparison.

Sources: Wang et al. 2024 (Mal d 1 in Northern China), Decuyper et al. 2020 (basophil activation testing for Mal d 3 in Barcelona), Osterballe et al. 2003 (apple skin prick test). What this means for you: if your main concern is apple allergy itself, Mal d 1 IgE and a skin prick test with fresh apple are more informative. Mal d 3 IgE earns its place when the question is whether a broader nsLTP problem is hiding behind your symptoms.

Why One Reading Is Not Enough

IgE-based component tests are best understood as one data point in a sensitization pattern that evolves with age, exposure, and treatment. Studies in Polish children show that the molecular sensitization profile changes as people grow, with new components appearing and others fading. A single positive Mal d 3 IgE at one moment in time does not predict what your immune system will look like in two years, and it does not tell you whether you are sensitized to other nsLTPs unless those are also tested.

A reasonable cadence: get a baseline alongside other relevant components (Mal d 1, peach Pru p 3, hazelnut Cor a 8, peanut Ara h 9, mugwort Art v 3), retest in 6 to 12 months if you make dietary changes or start immunotherapy, and then annually if you are tracking a known sensitization. Single readings should be paired with a careful clinical history rather than acted on in isolation.

What an Unexpected Result Should Prompt

If Mal d 3 IgE is positive, the next step is rarely to give up apples. It is to expand the picture. Consider ordering, or asking your allergist to interpret, the peach LTP (Pru p 3), hazelnut LTP (Cor a 8), walnut LTP (Jug r 3), peanut LTP (Ara h 9), and mugwort LTP (Art v 3) components. The combination tells you whether you have a focused or broad nsLTP profile.

Bring the panel and your symptom history to a board-certified allergist, ideally one familiar with component-resolved diagnostics. They can determine whether an oral food challenge is warranted to distinguish sensitization from true allergy, since IgE positivity alone does not confirm a clinical reaction. If you have ever had unexplained anaphylaxis, share that history early. A positive nsLTP profile in someone with a history of systemic reactions is a different conversation than a positive result in someone who simply tested out of curiosity.

When Results Can Be Misleading

• Sensitization is not allergy: A positive Mal d 3 IgE means your immune system has made antibodies. It does not mean you will react when you eat an apple. Many people with positive IgE eat the food without symptoms.
• Geographic context matters: The same result carries very different clinical weight in Spain than in Sweden or Northern China. Interpretation requires knowing your exposure history and where most of your symptoms have occurred.
• Total IgE can affect interpretation: People with very high overall IgE levels (such as those with severe atopic dermatitis) can have low-level positive results that are clinically meaningless. Pair the component result with your total IgE and clinical picture.
• Recent allergen exposure or treatment: If you have recently undergone allergen immunotherapy, your component IgE levels may be shifting in response to treatment, not reflecting a stable baseline.